-
公开(公告)号：EP1237849A1
公开(公告)日：2002-09-11
申请号：EP00973061.5
申请日：2000-11-06
发明人： SELWOOD, David,Uni College London,The Wolfson , GLEN, Robert,Uni College London,The Wolfson , REYNOLDS, Karen,Uni College London,The Wolfson , WISHART, Grant,Uni College London,The Wolfson
IPC分类号： C07C235/84 , C07C235/50 , C07C235/60 , C07D213/82 , C07C233/78 , C07C235/82 , C07D307/68 , C07C275/36 , C07C275/38 , C07C275/24 , A61K31/165 , A61K31/455 , A61K31/34 , A61K31/17
CPC分类号： C07D213/643 , C07C233/36 , C07C233/37 , C07C233/40 , C07C233/62 , C07C233/78 , C07C235/34 , C07C235/50 , C07C235/60 , C07C235/78 , C07C235/82 , C07C235/84 , C07C237/40 , C07C275/16 , C07C275/24 , C07C275/26 , C07C275/30 , C07C275/36 , C07C275/38 , C07C275/42 , C07C323/62 , C07C323/67 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2603/50 , C07D207/16 , C07D207/34 , C07D209/18 , C07D209/22 , C07D209/42 , C07D213/82 , C07D215/42 , C07D215/52 , C07D231/14 , C07D231/16 , C07D231/40 , C07D237/30 , C07D239/38 , C07D239/95 , C07D241/24 , C07D277/28 , C07D277/30 , C07D277/56 , C07D295/13 , C07D307/68 , C07D311/24 , C07D333/36 , C07D333/38 , C07D333/56 , C07D401/12 , C07D405/04 , C07D409/04 , C07D417/04 , C07D471/04 , C07D495/04
摘要： Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase, wherein: R1 and R2 are the same or different and each represent a C1-C6 alkyl group, or R1 and R2 together form a C3-C6 alkylene group; Z is a C1-C4 alkylene group; P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein; W is -O-, -S-, or -NR3, wherein R3 is hydrogen or C1-C6 alkyl; Y is a moiety -U-V- wherein V is a direct bond or a C1-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)- wherein R is hydrogen, hydroxy or C1-C6 alkyl; X is -O- or -NR6- wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C1-C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocyclyl or heterocyclyl, or R4 is a group -COR', -CO2R', -S(O)2R' or -CONR'R' wherein R' is hydrogen, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and R' is aryl, heteroaryl, carbocyclyl or heterocyclyl.
摘要翻译： 式（I）化合物或其药学上可接受的盐在制备用于活化可溶性鸟苷酸环化酶的药物中的用途，其中：R1和R2相同或不同，并且各自表示C1-C6 烷基或R 1和R 2一起形成C 3 -C 6亚烷基; Z是C1-C4亚烷基; P是直接键或部分-X-，-Y-，-W-，-XY-，-YW-或-XYW-，其中; W是-O - ， - S - 或-NR 3，其中R 3是氢或C 1 -C 6烷基; Y是部分-UV-，其中V是直接键或C1-C6亚烷基，U是-CS-，-CO-，-S（O）2 - 或-C（= NR） - ，其中R是氢 ，羟基或C 1 -C 6烷基; X是-O-或-NR 6 - ，其中R 6是氢，C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基，芳基或杂芳基; 其中R为 - （C 1 -C 6烷基） - ， - （C 2 -C 6烯基） - （C 1 -C 6）烷基，C 2 -C 6烯基，C 2 -C 6炔基，芳基，杂芳基，碳环基，杂环基， 或 - （C 2 -C 6炔基） - 和A是芳基，杂芳基，碳环基或杂环基，或R 4是基团-COR“，-CO 2 R”，-S（O）2 R“或-CONR'R”，其中R' 氢，C 1 -C 6烷基，C 2 -C 6烯基或C 2 -C 6炔基，R“是芳基，杂芳基，碳环基或杂环基。
-
32.发明公开METHOD AND APPARATUS FOR MONITORING AND MAINTAINING THE CONSISTENCY OF DISTRIBUTED DOCUMENTS 审中-公开方法和设备监控和维护所分发的文档的一致性
公开(公告)号：EP1221113A2
公开(公告)日：2002-07-10
申请号：EP00940552.3
申请日：2000-06-15
发明人： ZISMAN, Andrea,University College London , FINKELSTEIN, Anthony,University College London , ELLMER, Ernst,University College London , SMOLKO, Danila,University College London , EMMERICH, Wolfgang,University College London
CPC分类号： G06F17/30014 , Y10S707/99942 , Y10S707/99943 , Y10S707/99944 , Y10S707/99945
摘要： A computer network comprising a plurality of terminals (1-4) connected via a communications network 5 is provided. In each of the terminals (1-4) application software (15) for generating XML source documents is provided. XML source documents created using the application software (15) are then sent to one of the terminals (4) having stored therein a consistency checker (10). The consistency checker (10) processes the source document together with a set of consistency rules (14) to generate an output presentation identifying data within the source documents which does or does not fulfil the requirements of consistency relationships defined by the consistency rules (14).
-
公开(公告)号：EP1218734A1
公开(公告)日：2002-07-03
申请号：EP00962662.3
申请日：2000-09-14
发明人： Beard, Paul , Mills, Timothy Noel
CPC分类号： A61B5/0059 , A61B5/0066 , A61B5/0097 , G01H9/002 , G01N21/1702 , G01S15/8968 , G10K15/046
摘要： An interferometer sensor has a two-dimensional sensor head (1) comprising a polymer film (4) of substantially uniform thickness. An interrogating signal (12) is provided to the sensor head, the interrogation signal extending across the area of the sensor head and being incident normally to the sensor head (1). An optical sensing device (16) is arranged to receive an optical output signal from the sensor head at a location remote from the sensor head. The sensor converts ultrasound signals appearing over a two dimensional surface to an optical signal pattern, using a polymer interferometer sensing film. Spatial discretisation of the ultrasound signal pattern is performed by an optical sensing device. Such optical devices can be arranged having sufficiently high resolution to enable beam-steering imaging to be performed, including imaging outside the footprint of the sensor head.
摘要翻译： 干涉仪传感器具有包括厚度基本均匀的聚合物膜（4）的二维传感器头（1）。 询问信号（12）被提供给传感器头，询问信号延伸穿过传感器头的区域并正常地入射到传感器头（1）。 光学感测装置（16）被布置成在远离传感器头的位置处接收来自传感器头的光学输出信号。 该传感器使用聚合物干涉仪感测膜将出现在二维表面上的超声信号转换为光学信号图案。 超声信号图案的空间离散化由光学传感装置执行。 这样的光学装置可以被布置为具有足够高的分辨率以使得能够执行光束转向成像，包括在传感器头的占地面积之外的成像。
-
公开(公告)号：EP1203095A2
公开(公告)日：2002-05-08
申请号：EP00948183.9
申请日：2000-07-28
发明人： CHARLES, Ian G.,Wolfson Inst. for Biolog. Res. , XU, Weiming,Wolfson Inst. for Biomedic. Res. , LIU, Lizhi,Wolfson Inst. for Biomedic. Res.
CPC分类号： C12N15/635 , C12N2503/02 , C12N2510/00
摘要： A method for identifying a modulator of NOS activity comprises: (i) providing a polynucleotide construct which comprises: (a) a promoter operably linked to a coding sequence, wherein the promoter is responsive to ecdysone or an analog thereof and the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; (ii) contacting a test substance with the construct under conditions that would permit the expression and activity of the NOS encoded by the coding sequence in the absence of the test substance; and (iii) determining thereby whether the said substance modulates NOS activity. Modulators of nitric oxide synthase activity can be used in the treatment of conditions in which the abnormal metabolism of nitric oxide is implicated.
-
公开(公告)号：EP1200822A1
公开(公告)日：2002-05-02
申请号：EP00948099.7
申请日：2000-07-11
发明人： Yeaman, SteveSchool of Biochemistry and Genetics , Shepherd, PeterUniversity College London , Zorzano, AntonioUniversitat de Borcelona
CPC分类号： G01N33/5061 , G01N33/5008 , G01N33/502 , G01N33/5044 , G01N33/5067 , G01N33/74 , G01N2333/62
摘要： This invention relates to a method of studying insulin action in a cell line, wherein the cell line is an immortalised cell line. This method comprises contacting the cell line with a factor, and determining whether the factor affects or mimics insulin action.
-
36.发明公开
公开(公告)号：EP0903147A3
公开(公告)日：2002-02-27
申请号：EP98307522.7
申请日：1998-09-16
CPC分类号： C07K14/474 , A61K38/00
摘要： A Schwann cell mitogen that is capable of being upregulated during regeneration of neuronal cells or tissue is described. In a particular embodiment, there is provided the use of a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof in the manufacture of a medicament to act as a Schwann cell mitogen.
摘要翻译： 描述了能够在神经元细胞或组织再生期间被上调的雪旺细胞丝裂原。 在一个具体实施方案中，提供了包含SEQ ID No.1所示序列或其变体，衍生物或同系物的蛋白质在制备用作施万细胞丝裂原的药物中的用途。
-
公开(公告)号：EP0858294B1
公开(公告)日：2001-11-07
申请号：EP96928574.1
申请日：1996-08-30
CPC分类号： A61B17/3401 , A61B2017/00911 , A61B2090/0813 , A61M25/06
摘要： A medical needle is made of non-metallic, non-magnetic materials such that medical interventional procedures requiring needle access to people, animals or isolated tissues can be performed in a Magnetic Resonance Imaging (MRI) scanner without significant artefact or image distortion. The dimensions of the needle are adaptable to the task required.
-
公开(公告)号：EP1146908A1
公开(公告)日：2001-10-24
申请号：EP00901236.0
申请日：2000-01-27
CPC分类号： C07H21/04 , A61K31/711 , A61K38/00 , C12N15/111 , C12N15/1138 , C12N2310/11 , C12N2320/32
摘要： A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
-
公开(公告)号：EP1144605A2
公开(公告)日：2001-10-17
申请号：EP00901731.0
申请日：2000-01-26
发明人： VALLANCE, Patrick John Thompson,St. Martins House , LEIPER, James Mitchell,St. Martins House , WHITLEY, Guy St. John,St. George's Hospital , CHARLES, Ian George,St. Martins House
IPC分类号： C12N9/78 , C12N15/63 , C07K16/40 , A01K67/00 , C12Q1/34 , A61P3/00 , A61P13/00 , A61P9/00 , A61P25/18 , A61P21/00 , A61P19/00
CPC分类号： C12N9/78
摘要： Two dimethylarginine dimethylaminohydrolase (DDAH) genes and related genes from Streptomyces coelicolor, Pseudomonas aeruginosa and Mycobacterium tuberculosis have been cloned from humans. These genes and related genes Streptomyces coelicolor, Pseudomonas aeruginosa and Mycobacterium tuberculosis can be used to screen for inhibitors and activators of activity and/or expression of DDAHs. Inhibitors and activators of activity and/or expression of DDAHs are useful in the treatment of conditions in which abnormal metabolism of nitric oxide is implicated.
-
40.发明公开
公开(公告)号：EP1141334A2
公开(公告)日：2001-10-10
申请号：EP99963641.8
申请日：1999-12-23
IPC分类号： C12N15/55
摘要： Glycosyl phosphatidy linositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.
-
-
-
-
-
-
-
-
-
搜索结果
316 条记录 (耗时 0.023 秒)
